Thursday, October 6, 2016

Delta D3


Generic Name: vitamin d and related compounds (Oral route, Parenteral route)


Commonly used brand name(s)

In the U.S.


  • Calciferol

  • Delta D3

  • DHT

  • DHT Intensol

  • Drisdol

  • Hectorol

  • Rocaltrol

  • Vitamin D

  • Zemplar

In Canada


  • D-Vi-Sol

  • Radiostol Forte

Available Dosage Forms:


  • Capsule, Liquid Filled

  • Capsule

  • Solution

  • Tablet

  • Oil

  • Liquid

  • Tablet, Chewable

Uses For Delta D3


Vitamins are compounds that you must have for growth and health. They are needed in small amounts only and are available in the foods that you eat. Vitamin D is necessary for strong bones and teeth.


Lack of vitamin D may lead to a condition called rickets, especially in children, in which bones and teeth are weak. In adults it may cause a condition called osteomalacia, in which calcium is lost from bones so that they become weak. Your doctor may treat these problems by prescribing vitamin D for you. Vitamin D is also sometimes used to treat other diseases in which calcium is not used properly by the body.


Ergocalciferol is the form of vitamin D used in vitamin supplements.


Some conditions may increase your need for vitamin D. These include:


  • Alcoholism

  • Intestine diseases

  • Kidney disease

  • Liver disease

  • Overactivity of the parathyroid glands with kidney failure

  • Pancreas disease

  • Surgical removal of stomach

In addition, individuals and breast-fed infants who lack exposure to sunlight, as well as dark-skinned individuals, may be more likely to have a vitamin D deficiency. Increased need for vitamin D should be determined by your health care professional.


Alfacalcidol, calcifediol, calcitriol, and dihydrotachysterol are forms of vitamin D used to treat hypocalcemia (not enough calcium in the blood). Alfacalcidol, calcifediol, and calcitriol are also used to treat certain types of bone disease that may occur with kidney disease in patients who are undergoing kidney dialysis.


Claims that vitamin D is effective for treatment of arthritis and prevention of nearsightedness or nerve problems have not been proven. Some psoriasis patients may benefit from vitamin D supplements; however, controlled studies have not been performed.


Injectable vitamin D is given by or under the supervision of a health care professional. Some strengths of ergocalciferol and all strengths of alfacalcidol, calcifediol, calcitriol, and dihydrotachysterol are available only with your doctor's prescription. Other strengths of ergocalciferol are available without a prescription. However, it may be a good idea to check with your health care professional before taking vitamin D on your own. Taking large amounts over long periods may cause serious unwanted effects.


Importance of Diet


For good health, it is important that you eat a balanced and varied diet. Follow carefully any diet program your health care professional may recommend. For your specific dietary vitamin and/or mineral needs, ask your health care professional for a list of appropriate foods. If you think that you are not getting enough vitamins and/or minerals in your diet, you may choose to take a dietary supplement.


Vitamin D is found naturally only in fish and fish-liver oils. However, it is also found in milk (vitamin D–fortified). Cooking does not affect the vitamin D in foods. Vitamin D is sometimes called the "sunshine vitamin" since it is made in your skin when you are exposed to sunlight. If you eat a balanced diet and get outside in the sunshine at least 1.5 to 2 hours a week, you should be getting all the vitamin D you need.


Vitamins alone will not take the place of a good diet and will not provide energy. Your body also needs other substances found in food such as protein, minerals, carbohydrates, and fat. Vitamins themselves often cannot work without the presence of other foods. For example, fat is needed so that vitamin D can be absorbed into the body.


The daily amount of vitamin D needed is defined in several different ways.


  • For U.S.—

  • Recommended Dietary Allowances (RDAs) are the amount of vitamins and minerals needed to provide for adequate nutrition in most healthy persons. RDAs for a given nutrient may vary depending on a person's age, sex, and physical condition (e.g., pregnancy).

  • Daily Values (DVs) are used on food and dietary supplement labels to indicate the percent of the recommended daily amount of each nutrient that a serving provides. DV replaces the previous designation of United States Recommended Daily Allowances (USRDAs).

  • For Canada—

  • Recommended Nutrient Intakes (RNIs) are used to determine the amounts of vitamins, minerals, and protein needed to provide adequate nutrition and lessen the risk of chronic disease.

In the past, the RDA and RNI for vitamin D have been expressed in Units (U). This term has been replaced by micrograms (mcg) of vitamin D.


Normal daily recommended intakes in mcg and Units are generally defined as follows:


































PersonsU.S.Canada
mcgUnitsmcgUnits
Infants and children birth to

3 years of age
7.5-10300-4005–10200–400
Children 4 to 6 years of age104005200
Children 7 to 10 years of age104002.5–5100–200
Adolescents and adults5–10200–4002.5–5100–200
Pregnant and breast-feeding

females
104005–7.5200–300

Remember:


  • The total amount of each vitamin that you get every day includes what you get from the foods that you eat and what you may take as a supplement.

  • Your total amount should not be greater than the RDA or RNI, unless ordered by your doctor. Taking too much vitamin D over a period of time may cause harmful effects

Before Using Delta D3


If you are taking a dietary supplement without a prescription, carefully read and follow any precautions on the label. For these supplements, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to medicines in this group or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Problems in children have not been reported with intake of normal daily recommended amounts. Some studies have shown that infants who are totally breast-fed, especially with dark-skinned mothers, and have little exposure to sunlight may be at risk of vitamin D deficiency. Your health care professional may prescribe a vitamin/mineral supplement that contains vitamin D. Some infants may be sensitive to even small amounts of alfacalcidol, calcifediol, calcitriol, dihydrotachysterol, or ergocalciferol. Also, children may show slowed growth when receiving large doses of alfacalcidol, calcifediol, calcitriol, dihydrotachysterol, or ergocalciferol for a long time.


Studies on doxercalciferol or paricalcitol have been done only in adult patients, and there is no specific information comparing the use of doxercalciferol or paricalcitol in children with use in other age groups.


Geriatric


Problems in older adults have not been reported with intake of normal daily recommended amounts. Studies have shown that older adults may have lower blood levels of vitamin D than younger adults, especially those who have little exposure to sunlight. Your health care professional may recommend that you take a vitamin supplement that contains vitamin D.


Pregnancy


It is especially important that you are receiving enough vitamin D when you become pregnant and that you continue to receive the right amounts of vitamins throughout your pregnancy. The healthy growth and development of the fetus depend on a steady supply of nutrients from the mother.


You may need vitamin D supplements if you are a strict vegetarian (vegan-vegetarian) and/or have little exposure to sunlight and do not drink vitamin D-fortified milk.


Taking too much alfacalcidol, calcifediol, calcitriol, dihydrotachysterol, or ergocalciferol can also be harmful to the fetus. Taking more than your health care professional has recommended can cause your baby to be more sensitive than usual to its effects, can cause problems with a gland called the parathyroid, and can cause a defect in the baby's heart.


Doxercalciferol or paricalcitol have not been studied in pregnant women. However, studies in animals have shown that paricalcitol causes problems in newborns. Before taking this medicine, make sure your doctor knows if you are pregnant or if you may become pregnant.


Breast Feeding


It is especially important that you receive the right amounts of vitamins so that your baby will also get the vitamins needed to grow properly. Infants who are totally breast-fed and have little exposure to the sun may require vitamin D supplementation. However, taking large amounts of a dietary supplement while breast-feeding may be harmful to the mother and/or baby and should be avoided.


Only small amounts of alfacalcidol, calcifediol, calcitriol, or dihydrotachysterol pass into breast milk and these amounts have not been reported to cause problems in nursing babies.


It is not known whether doxercalciferol or paricalcitol passes into breast milk. Be sure you have discussed the risks and benefits of the supplement with your doctor.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.


Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of dietary supplements in this class. Make sure you tell your doctor if you have any other medical problems, especially:


  • Heart or blood vessel disease—Alfacalcidol, calcifediol, calcitriol, or dihydrotachysterol may cause hypercalcemia (high blood levels of calcium), which may make these conditions worse.

  • Kidney disease—High blood levels of alfacalcidol, calcifediol, calcitriol, dihydrotachysterol, or ergocalciferol may result, which may increase the chance of side effects.

  • Sarcoidosis—May increase sensitivity to alfacalcidol, calcifediol, calcitriol, dihydrotachysterol, or ergocalciferol and increase the chance of side effects

Proper Use of vitamin d and related compounds

This section provides information on the proper use of a number of products that contain vitamin d and related compounds. It may not be specific to Delta D3. Please read with care.


For use as a dietary supplement:


  • Do not take more than the recommended daily amount. Vitamin D is stored in the body, and taking too much over a period of time can cause poisoning and even death.

If you have any questions about this, check with your health care professional.


For individuals taking the oral liquid form of this dietary supplement:


  • This preparation should be taken by mouth even though it comes in a dropper bottle.

  • This dietary supplement may be dropped directly into the mouth or mixed with cereal, fruit juice, or other food.

While you are taking alfacalcidol, calcifediol, calcitriol, dihydrotachysterol, doxercalciferol or paricalcitol , your health care professional may want you to follow a special diet or take a calcium supplement. Be sure to follow instructions carefully. If you are already taking a calcium supplement or any medicine containing calcium, make sure your health care professional knows.


Dosing


The dose medicines in this class will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of these medicines. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For alfacalcidol

  • To treat bone disease in kidney patients undergoing kidney dialysis:
    • For oral dosage form (capsules):
      • Adults and teenagers—At first, 1 microgram (mcg) a day. Your doctor may change your dose if needed. However, most people will take not more than 3 mcg a day.


    • For oral dosage form (drops):
      • Adults and teenagers—At first, 1 microgram (mcg) a day. Your doctor may change your dose if needed. However, most people will take not more than 3 mcg a day.


    • For oral dosage form (solution):
      • Adults and teenagers—At first, 1 mcg a day. Your doctor may change your dose if needed. However, most people will take not more than 3 mcg a day.


    • For parenteral dosage form (injection):
      • Adults and teenagers—At first, 1 mcg a day. Your doctor may change your dose if needed. However, most people will take not more than 12 mcg a week.



  • To treat diseases in which calcium is not used properly by the body:
    • For oral dosage form (capsules):
      • Adults and teenagers—At first, 0.25 microgram (mcg) a day. Your doctor may change your dose if needed. However, most people will take not more than 1 mcg a day.


    • For oral dosage form (drops):
      • Adults and teenagers—At first, 0.25 microgram (mcg) a day. Your doctor may change your dose if needed. However, most people will take not more than 1 mcg a day.


    • For oral dosage form (solution):
      • Adults and teenagers—At first, 0.25 mcg a day. Your doctor may change your dose if needed. However, most people will take not more than 1 mcg a day.



  • For calcifediol

  • To treat diseases in which calcium is not used properly by the body or to treat bone disease in kidney patients undergoing kidney dialysis:
    • For oral dosage form (capsules):
      • Adults, teenagers, and children over 10 years of age—At first, 300 to 350 micrograms (mcg) a week, taken in divided doses either once a day or every other day. Your doctor may change your dose if needed.

      • Children 2 to 10 years of age—50 mcg a day.

      • Children up to 2 years of age—20 to 50 mcg a day.



  • To treat diseases in which calcium is not used properly by the body or to treat bone disease in kidney patients undergoing kidney dialysis:
    • For oral dosage forms (capsules and solution):
      • Adults, teenagers, and children—At first, 0.25 micrograms (mcg) a day. Your doctor may change your dose if needed.


    • For parenteral dosage forms (injection):
      • Adults and teenagers—At first, 0.5 mcg injected into a vein three times a week. Your doctor may change your dose if needed.

      • Children—Use and dose must be determined by your doctor.



  • For dihydrotachysterol

  • To treat diseases in which calcium is not used properly by the body:
    • For oral dosage forms (capsules, solution, or tablets):
      • Adults and teenagers—At first, 100 micrograms (mcg) to 2.5 milligrams (mg) a day. Your doctor may change your dose if needed.

      • Children—At first, 1 to 5 mg a day. Your doctor may change your dose if needed.



  • For doxercalciferol

  • To treat an overactive parathyroid gland in patients with kidney failure:
    • For oral dosage form (capsules):
      • Adults—10 micrograms (mcg) three times weekly at dialysis. The doctor may change your dose if needed.

      • Children—Use and dose must be determined by your doctor.



  • For ergocalciferol

  • The amount of vitamin D to meet normal daily recommended intakes will be different for different individuals. The following information includes only the average amounts of vitamin D.

  • To prevent deficiency, the amount taken by mouth is based on normal daily recommended intakes:
    • For oral dosage form (capsules):
      • For the U.S.

      • Adults and teenagers—5 to 10 micrograms (mcg) (200 to 400 Units) per day.

      • Pregnant and breast-feeding females—10 mcg (400 Units) per day.

      • Children 4 to 10 years of age—10 mcg (400 Units) per day.

      • Children birth to 3 years of age—7.5 to 10 mcg (300 to 400 Units) per day.

      • For Canada

      • Adults and teenagers—2.5 to 5 mcg (100 to 200 Units) per day.

      • Pregnant and breast-feeding females—5 to 7.5 mcg (200 to 300 Units) per day.

      • Children 7 to 10 years of age—2.5 to 5 mcg (100 to 200 Units) per day.

      • Children 4 to 6 years of age—5 mcg (200 Units) per day.

      • Children birth to 3 years of age—5 to 10 mcg (200 to 400 Units) per day.



  • To treat deficiency:
    • Adults, teenagers, and children—Treatment dose is determined by prescriber for each individual based on severity of deficiency.


  • To treat diseases in which calcium and phosphate are not used properly by the body:
    • Adults and teenagers—At first, 1000 to 500,000 Units a day. The doctor may change your dose if needed.

    • Children—At first, 1000 to 200,000 Units a day. The doctor may change your dose if needed.


  • For paricalcitol

  • To treat an overactive parathyroid gland in patients with kidney failure:
    • For oral dosage form (capsules):
      • Adults—1 to 2 micrograms (mcg) one time per day or 2 to 4 mcg three times a week (not more often than every other day). The doctor may change your dose if needed.

      • Children—Use and dose must be determined by your doctor.


    • For parenteral dosage form (injection):
      • Adults—0.04 to 0.1 micrograms (mcg) per kg no more than every other day during dialysis. The doctor may change your dose if needed.

      • Children—Use and dose must be determined by your doctor.



Missed Dose


Call your doctor or pharmacist for instructions.


For use as a dietary supplement: If you miss taking a dietary supplement for one or more days there is no cause for concern, since it takes some time for your body to become seriously low in vitamins. However, if your health care professional has recommended that you take this dietary supplement, try to remember to take it as directed every day.


If you are taking this medicine for a reason other than as a dietary supplement and you miss a dose and your dosing schedule is:


  • One dose every other day—Take the missed dose as soon as possible if you remember it on the day it should be taken. However, if you do not remember the missed dose until the next day, take it at that time. Then skip a day and start your dosing schedule again. Do not double doses

  • One dose a day—Take the missed dose as soon as possible. Then go back to your regular dosing schedule. However, if you do not remember the missed dose until the next day, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

  • More than one dose a day—Take the missed dose as soon as possible. Then go back to your regular dosing schedule. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

If you have any questions about this, check with your health care professional.


Storage


Keep out of the reach of children.


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Do not keep outdated medicine or medicine no longer needed.


Precautions While Using Delta D3


For individuals taking vitamin D without a prescription:


  • Vitamin D is stored in the body; therefore, when you take more than the body needs, it will build up in the body. This may lead to poisoning. Problems are more likely to occur in:
    • Adults taking 20,000 to 80,000 Units a day and more for several weeks or months.

    • Children taking 2,000 to 4,000 Units a day for several months.


If you are taking this medicine for a reason other than as a dietary supplement, your doctor should check your progress at regular visits to make sure that it does not cause unwanted effects.


Do not take any nonprescription (over-the-counter [OTC]) medicine or dietary supplement that contains calcium, phosphorus, or vitamin D while you are taking any of these dietary supplements unless you have been told to do so by your health care professional. The extra calcium, phosphorus, or vitamin D may increase the chance of side effects.


Do not take antacids or other medicines containing magnesium while you are taking any of these medicines. Taking these medicines together may cause unwanted effects.


Delta D3 Side Effects


Along with its needed effects, a dietary supplement may cause some unwanted effects. Alfacalcidol, calcifediol, calcitriol, dihydrotachysterol, and ergocalciferol do not usually cause any side effects when taken as directed. However, taking large amounts over a period of time may cause some unwanted effects that can be serious.


Check with your doctor immediately if any of the following side effects occur:


Late symptoms of severe overdose
  • High blood pressure

  • high fever

  • irregular heartbeat

  • stomach pain (severe)

Check with your doctor as soon as possible if any of the following side effects occur:


Early symptoms of overdose
  • Bone pain

  • constipation (especially in children or adolescents)

  • diarrhea

  • drowsiness

  • dryness of mouth

  • headache (continuing)

  • increased thirst

  • increase in frequency of urination, especially at night, or in amount of urine

  • irregular heartbeat

  • itching skin

  • loss of appetite

  • metallic taste

  • muscle pain

  • nausea or vomiting (especially in children or adolescents)

  • unusual tiredness or weakness

Late symptoms of overdose
  • Bone pain

  • calcium deposits (hard lumps) in tissues outside of the bone

  • cloudy urine

  • drowsiness

  • increased sensitivity of eyes to light or irritation of eyes

  • itching of skin

  • loss of appetite

  • loss of sex drive

  • mood or mental changes

  • muscle pain

  • nausea or vomiting

  • protein in the urine

  • redness or discharge of the eye, eyelid, or lining of the eyelid

  • runny nose

  • weight loss

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


Diethylpropion


dye-eth-il-PROE-pee-on hye-droe-KLOR-ide


Commonly used brand name(s)

In the U.S.


  • Tenuate

  • Tenuate Dospan

Available Dosage Forms:


  • Tablet, Extended Release

  • Tablet

Therapeutic Class: Appetite Suppressant, Centrally Acting


Chemical Class: Diethylpropion


Uses For diethylpropion


Diethylpropion is used as part of a short-term plan, along with a low calorie diet, for weight reduction. It is used in obese patients who have not been able to lose weight with diet and exercise alone. Diethylpropion belongs to the group of medicines known as appetite suppressants.


diethylpropion is available only with your doctor's prescription.


Before Using diethylpropion


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For diethylpropion, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to diethylpropion or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies have not been performed on the relationship of age to the effects of diethylpropion in children younger than 17 years of age. Safety and efficacy have not been established.


Geriatric


Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of diethylpropion in the elderly. However, elderly patients are more likely to have age-related kidney problems, which may require caution and an adjustment in the dose for patients receiving diethylpropion.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersBAnimal studies have revealed no evidence of harm to the fetus, however, there are no adequate studies in pregnant women OR animal studies have shown an adverse effect, but adequate studies in pregnant women have failed to demonstrate a risk to the fetus.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking diethylpropion, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using diethylpropion with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Brofaromine

  • Clorgyline

  • Furazolidone

  • Iproniazid

  • Isocarboxazid

  • Lazabemide

  • Linezolid

  • Moclobemide

  • Nialamide

  • Pargyline

  • Phenelzine

  • Procarbazine

  • Rasagiline

  • Selegiline

  • Sibutramine

  • Thioridazine

  • Toloxatone

  • Tranylcypromine

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of diethylpropion. Make sure you tell your doctor if you have any other medical problems, especially:


  • Agitated state or

  • Arteriosclerosis (hardening of the arteries), advanced or

  • Drug abuse or dependence, history of or

  • Glaucoma or

  • Heart problems (e.g., heart murmur, valvular heart disease) or

  • Hypertension (high blood pressure), severe or

  • Hyperthyroidism (overactive thyroid) or

  • Pulmonary hypertension (increased blood pressure in the lungs)—Should not be used in patients with these conditions.

  • Heart or blood vessel disease or

  • Heart rhythm problems (e.g., arrhythmia) or

  • Hypertension (high blood pressure), mild to moderate or

  • Mental illness or

  • Seizures or epilepsy—Use with caution. May make these conditions worse.

  • Kidney disease—Use with caution. Higher blood levels of diethylpropion can occur, which increases the risk of serious side effects.

Proper Use of diethylpropion


Take diethylpropion only as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. If too much is taken, it may become habit-forming (causing mental or physical dependence).


diethylpropion is available in two forms: the immediate-release tablets and the controlled-release tablets. Ask your doctor which dosage form is right for you.


Swallow the controlled-release tablets whole. Do not break, crush, or chew it.


Carefully follow your doctor's instructions for a reduced-calorie diet plan and regular exercise. Talk with your doctor before starting any exercise program.


Dosing


The dose of diethylpropion will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of diethylpropion. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For treatment of obesity:
    • For oral dosage form (immediate-release tablets):
      • Adults and teenagers 17 years of age and older—25 milligrams (mg) three times a day, taken one hour before meals, and in mid evening to overcome night hunger.

      • Children 16 years of age and younger—Use is not recommended.


    • For oral dosage form (controlled-release tablets):
      • Adults and teenagers 17 years of age and older—75 milligrams (mg) once a day, taken usually in mid morning.

      • Children 16 years of age and younger—Use is not recommended.



Missed Dose


If you miss a dose of diethylpropion, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Ask your healthcare professional how you should dispose of any medicine you do not use.


Precautions While Using diethylpropion


It is very important that your doctor check your progress at regular visits to make sure that diethylpropion is working properly and does not cause any unwanted effects.


Do not use diethylpropion if you are also using similar medicines such as benzphetamine, mazindol, phendimetrazine, phentermine, Bontril®, Didrex®, or Suprenza™. Also, do not use diethylpropion if you have used an MAO inhibitor (MAOI) such as Eldepryl®, Marplan®, Nardil®, or Parnate® within the past 14 days. Using these medicines together may cause serious unwanted effects.


diethylpropion may be habit-forming. If you think diethylpropion is not working properly after you have taken it for 4 weeks, do not increase the dose. Instead, check with your doctor.


Stop using diethylpropion and check with your doctor right away if you notice a decrease in your ability to exercise, if you faint, or if you have chest pain, swelling of your feet or lower legs, or trouble with breathing. These may be symptoms of a very serious heart or lung problem.


diethylpropion may cause some people to become dizzy, lightheaded, or less alert than they are normally. Make sure you know how you react to diethylpropion before you drive, use machines, or do anything else that could be dangerous if you are dizzy or not alert.


diethylpropion will add to the effects of alcohol and other CNS depressants (medicines that make you drowsy or less alert). Some examples of CNS depressants are antihistamines or medicine for hay fever, other allergies, or colds; sedatives, tranquilizers, or sleeping medicine; prescription pain medicine or narcotics; medicine for seizures (such as barbiturates); muscle relaxants; or anesthetics, including some dental anesthetics. Check with your medical doctor or dentist before taking any of the above while you are taking diethylpropion.


For diabetic patients: diethylpropion may affect blood sugar levels. If you notice a change in the results of your blood or urine sugar tests or if you have any questions, check with your doctor.


Do not take other medicines unless they have been discussed with your doctor. This includes prescription and nonprescription (over-the-counter) medicines, dietary supplements, herbal remedies, or medicines for appetite control, asthma, colds, cough, hay fever, and sinus problems.


diethylpropion Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


Rare
  • Seeing, hearing, or feeling things that are not there

  • severe mental changes

  • shortness of breath

Incidence not known
  • Black, tarry stools

  • blurred vision

  • burning while urinating

  • chest pain

  • chills

  • convulsions

  • cough or hoarseness

  • decreased ability to exercise

  • depression

  • difficult or labored breathing

  • difficult or painful urination

  • dizziness

  • fainting

  • false or unusual sense of well-being

  • fast, slow, pounding, or irregular heartbeat or pulse

  • fear or nervousness

  • fever with or without chills

  • frequent urination

  • general feeling of tiredness or weakness

  • headache

  • inability to speak

  • increased volume of pale, dilute urine

  • lower back or side pain

  • nosebleeds

  • numbness or tingling in the face, arms, or legs

  • restlessness

  • severe or sudden headache

  • shakiness in the legs, arms, hands, or feet

  • slurred speech

  • sore throat

  • sores, ulcers, or white spots on the lips or in the mouth

  • swelling of the feet or lower legs

  • swollen glands

  • temporary blindness

  • tightness in the chest

  • trembling or shaking of the hands or feet

  • trouble with breathing

  • twitching, twisting, or uncontrolled repetitive movements of the tongue, lips, face, arms, or legs

  • unusual bleeding or bruising

  • unusual tiredness or weakness

  • vision problems

  • weakness in the arm or leg on one side of the body, sudden and severe

  • wheezing

Get emergency help immediately if any of the following symptoms of overdose occur:


Symptoms of overdose
  • Abdominal or stomach cramps

  • bigger, dilated, or enlarged pupils (black part of the eye)

  • change in consciousness

  • confusion

  • diarrhea

  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position

  • increased sensitivity of the eyes to light

  • loss of consciousness

  • nausea

  • overactive reflexes

  • panic

  • physical attempt to injure

  • restlessness

  • sweating

  • violent actions

  • vomiting

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


Incidence not known
  • Abdominal or stomach discomfort

  • bruising

  • difficulty having a bowel movement (stool)

  • drowsiness

  • dry mouth

  • general feeling of discomfort or illness

  • hair loss

  • headache

  • hives or welts

  • indigestion

  • itching

  • large, flat, blue, or purplish patches in the skin

  • loss of appetite

  • muscle pain

  • passing of gas

  • redness of the skin

  • skin rash

  • sleeplessness

  • stomach fullness or discomfort

  • trouble sleeping

  • unable to sleep

  • unpleasant taste

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


Wednesday, October 5, 2016

Ditropan XL





Dosage Form: tablet, extended release
Ditropan XL®

(oxybutynin chloride)

Extended Release Tablets

Ditropan XL Description


Ditropan XL® (oxybutynin chloride) is an antispasmodic, anticholinergic agent. Each Ditropan XL® Extended Release Tablet contains 5 mg, 10 mg, or 15 mg of oxybutynin chloride USP, formulated as a once-a-day controlled-release tablet for oral administration. Oxybutynin chloride is administered as a racemate of R- and S-enantiomers.


Chemically, oxybutynin chloride is d,l (racemic) 4-diethylamino-2-butynyl phenylcyclohexylglycolate hydrochloride. The empirical formula of oxybutynin chloride is C22H31NO3•HCl.


Its structural formula is:



Oxybutynin chloride is a white crystalline solid with a molecular weight of 393.9. It is readily soluble in water and acids, but relatively insoluble in alkalis.


Ditropan XL® also contains the following inert ingredients: cellulose acetate, hypromellose, lactose, magnesium stearate, polyethylene glycol, polyethylene oxide, synthetic iron oxides, titanium dioxide, polysorbate 80, sodium chloride, and butylated hydroxytoluene.



System Components and Performance


Ditropan XL® uses osmotic pressure to deliver oxybutynin chloride at a controlled rate over approximately 24 hours. The system, which resembles a conventional tablet in appearance, comprises an osmotically active bilayer core surrounded by a semipermeable membrane. The bilayer core is composed of a drug layer containing the drug and excipients, and a push layer containing osmotically active components. There is a precision-laser drilled orifice in the semipermeable membrane on the drug-layer side of the tablet. In an aqueous environment, such as the gastrointestinal tract, water permeates through the membrane into the tablet core, causing the drug to go into suspension and the push layer to expand. This expansion pushes the suspended drug out through the orifice. The semipermeable membrane controls the rate at which water permeates into the tablet core, which in turn controls the rate of drug delivery. The controlled rate of drug delivery into the gastrointestinal lumen is thus independent of pH or gastrointestinal motility. The function of Ditropan XL® depends on the existence of an osmotic gradient between the contents of the bilayer core and the fluid in the gastrointestinal tract. Since the osmotic gradient remains constant, drug delivery remains essentially constant. The biologically inert components of the tablet remain intact during gastrointestinal transit and are eliminated in the feces as an insoluble shell.



Ditropan XL - Clinical Pharmacology


Oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. Oxybutynin chloride exhibits only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to ten times the antispasmodic activity. No blocking effects occur at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects).


Oxybutynin chloride relaxes bladder smooth muscle. In patients with conditions characterized by involuntary bladder contractions, cystometric studies have demonstrated that oxybutynin increases bladder (vesical) capacity, diminishes the frequency of uninhibited contractions of the detrusor muscle, and delays the initial desire to void. Oxybutynin thus decreases urgency and the frequency of both incontinent episodes and voluntary urination.


Antimuscarinic activity resides predominantly in the R-isomer. A metabolite, desethyloxybutynin, has pharmacological activity similar to that of oxybutynin in in vitro studies.



Pharmacokinetics


Absorption

Following the first dose of Ditropan XL® (oxybutynin chloride), oxybutynin plasma concentrations rise for 4 to 6 hours; thereafter steady concentrations are maintained for up to 24 hours, minimizing fluctuations between peak and trough concentrations associated with oxybutynin.


The relative bioavailabilities of R- and S-oxybutynin from Ditropan XL® are 156% and 187%, respectively, compared with oxybutynin. The mean pharmacokinetic parameters for R- and S-oxybutynin are summarized in Table 1. The plasma concentration-time profiles for R- and S-oxybutynin are similar in shape; Figure 1 shows the profile for R-oxybutynin.
































Table 1 Mean (SD) R- and S-Oxybutynin Pharmacokinetic Parameters Following a Single Dose of Ditropan XL® 10 mg (n=43)
Parameters (units)R-OxybutyninS-Oxybutynin
Cmax (ng/mL)1.0(0.6)1.8(1.0)
Tmax (h)12.7(5.4)11.8(5.3)
t1/2 (h)13.2(6.2)12.4(6.1)
AUC (0–48) (ng∙h/mL)18.4(10.3)34.2(16.9)
AUCinf (ng∙h/mL)21.3(12.2)39.5(21.2)


Figure 1. Mean R-oxybutynin plasma concentrations following a single dose of Ditropan XL® 10 mg and oxybutynin 5 mg administered every 8 hours (n=23 for each treatment).

Steady state oxybutynin plasma concentrations are achieved by Day 3 of repeated Ditropan XL® dosing, with no observed drug accumulation or change in oxybutynin and desethyloxybutynin pharmacokinetic parameters.


Ditropan XL® steady state pharmacokinetics were studied in 19 children aged 5–15 years with detrusor overactivity associated with a neurological condition (e.g., spina bifida). The children were on Ditropan XL® total daily dose ranging from 5 to 20 mg (0.10 to 0.77 mg/kg). Sparse sampling technique was used to obtain serum samples. When all available data are normalized to an equivalent of 5 mg per day Ditropan XL®, the mean pharmacokinetic parameters derived for R- and S-oxybutynin and R- and S-desethyloxybutynin are summarized in Table 2. The plasma-time concentration profiles for R- and S-oxybutynin are similar in shape; Figure 2 shows the profile for R-oxybutynin when all available data are normalized to an equivalent of 5 mg per day.
























Table 2 Mean ± SD R- and S-Oxybutynin and R- and S-Desethyloxybutynin Pharmacokinetic Parameters in Children Aged 5–15 Following Administration of 5 to 20 mg Ditropan XL® Once Daily (n=19), All Available Data Normalized to an Equivalent of Ditropan XL® 5 mg Once Daily
R-OxybutyninS-OxybutyninR- DesethyloxybutyninS- Desethyloxybutynin
Cmax (ng/mL)0.7 ± 0.41.3 ± 0.87.8 ± 3.74.2 ± 2.3
Tmax (h)5.05.05.05.0
AUC(ng∙h/mL)12.8 ± 7.023.7 ± 14.4125.1 ± 66.773.6 ± 47.7


Figure 2. Mean steady state (± SD) R-oxybutynin plasma concentrations following administration of 5 to 20 mg Ditropan XL® once daily in children aged 5–15. Plot represents all available data normalized to an equivalent of Ditropan XL® 5 mg once daily.

Food Effects


The rate and extent of absorption and metabolism of oxybutynin are similar under fed and fasted conditions.


Distribution

Oxybutynin is widely distributed in body tissues following systemic absorption. The volume of distribution is 193 L after intravenous administration of 5 mg oxybutynin chloride. Both enantiomers of oxybutynin are highly bound (>99%) to plasma proteins. Both enantiomers of N-desethyloxybutynin are also highly bound (>97%) to plasma proteins. The major binding protein is alpha-1 acid glycoprotein.


Metabolism

Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4 found mostly in the liver and gut wall. Its metabolic products include phenylcyclohexylglycolic acid, which is pharmacologically inactive, and desethyloxybutynin, which is pharmacologically active. Following Ditropan XL® administration, plasma concentrations of R- and S-desethyloxybutynin are 73% and 92%, respectively, of concentrations observed with oxybutynin.


Excretion

Oxybutynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine. Also, less than 0.1% of the administered dose is excreted as the metabolite desethyloxybutynin.


Dose Proportionality

Pharmacokinetic parameters of oxybutynin and desethyloxybutynin (Cmax and AUC) following administration of 5–20 mg of Ditropan XL® are dose proportional.


Special Populations

Geriatric


The pharmacokinetics of Ditropan XL® were similar in all patients studied (up to 78 years of age).



Pediatric


The pharmacokinetics of Ditropan XL® were evaluated in 19 children aged 5–15 years with detrusor overactivity associated with a neurological condition (e.g., spina bifida). The pharmacokinetics of Ditropan XL® in these pediatric patients were consistent with those reported for adults (see Tables 1 and 2, and Figures 1 and 2 above).



Gender


There are no significant differences in the pharmacokinetics of oxybutynin in healthy male and female volunteers following administration of Ditropan XL®.



Race


Available data suggest that there are no significant differences in the pharmacokinetics of oxybutynin based on race in healthy volunteers following administration of Ditropan XL®.



Renal Insufficiency


There is no experience with the use of Ditropan XL® in patients with renal insufficiency.



Hepatic Insufficiency


There is no experience with the use of Ditropan XL® in patients with hepatic insufficiency.



Drug-Drug Interactions


See PRECAUTIONS: Drug Interactions.



Clinical Studies


Ditropan XL® (oxybutynin chloride) was evaluated for the treatment of patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency in three controlled studies and one open-label study. The majority of patients were Caucasian (89.0%) and female (91.9%) with a mean age of 59 years (range, 18 to 98 years). Entry criteria required that patients have urge or mixed incontinence (with a predominance of urge) as evidenced by ≥ 6 urge incontinence episodes per week and ≥ 10 micturitions per day. Study 1 was a fixed-dose escalation design, whereas the other studies used a dose-adjustment design in which each patient's final dose was adjusted to a balance between improvement of incontinence symptoms and tolerability of side effects. Controlled studies included patients known to be responsive to oxybutynin or other anticholinergic medications, and these patients were maintained on a final dose for up to 2 weeks.


The efficacy results for the three controlled trials are presented in the following tables and figures.




Indications and Usage for Ditropan XL


Ditropan XL® (oxybutynin chloride) is a once-daily controlled-release tablet indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.


Ditropan XL® is also indicated in the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).



Contraindications


Ditropan XL® (oxybutynin chloride) is contraindicated in patients with urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma and in patients who are at risk for these conditions.


Ditropan XL® is also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product.



Warnings


Angioedema of the face, lips, tongue and/or larynx has been reported with oxybutynin. In some cases, angioedema occurred after the first dose. Angioedema associated with upper airway swelling may be life-threatening. If involvement of the tongue, hypopharynx, or larynx occurs, oxybutynin should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided.



Precautions



Central Nervous System Effects


Oxybutynin is associated with anticholinergic central nervous system (CNS) effects (see ADVERSE REACTIONS). A variety of CNS anticholinergic effects have been reported, including hallucinations, agitation, confusion and somnolence. Patients should be monitored for signs of anticholinergic CNS effects, particularly in the first few months after beginning treatment or increasing the dose. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.


Ditropan XL® should be used with caution in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.



General


Ditropan XL® (oxybutynin chloride) should be used with caution in patients with hepatic or renal impairment and in patients with myasthenia gravis due to the risk of symptom aggravation.



Urinary Retention


Ditropan XL® should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention (see CONTRAINDICATIONS).



Gastrointestinal Disorders


Ditropan XL® should be administered with caution to patients with gastrointestinal obstructive disorders because of the risk of gastric retention (see CONTRAINDICATIONS).


Ditropan XL®, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis and intestinal atony.


Ditropan XL® should be used with caution in patients who have gastroesophageal reflux and/or who are concurrently taking drugs (such as bisphosphonates) that can cause or exacerbate esophagitis.


As with any other nondeformable material, caution should be used when administering Ditropan XL® to patients with preexisting severe gastrointestinal narrowing (pathologic or iatrogenic). There have been rare reports of obstructive symptoms in patients with known strictures in association with the ingestion of other drugs in nondeformable controlled-release formulations.



Information for Patients


Patients should be informed that oxybutynin may produce angioedema that could result in life-threatening airway obstruction. Patients should be advised to promptly discontinue oxybutynin therapy and seek immediate medical attention if they experience edema of the tongue, edema of the laryngopharynx, or difficulty breathing.


Patients should be informed that heat prostration (fever and heat stroke due to decreased sweating) can occur when anticholinergics such as oxybutynin chloride are administered in the presence of high environmental temperature.


Because anticholinergic agents such as oxybutynin may produce drowsiness (somnolence) or blurred vision, patients should be advised to exercise caution.


Patients should be informed that alcohol may enhance the drowsiness caused by anticholinergic agents such as oxybutynin.


Patients should be informed that Ditropan XL® should be swallowed whole with the aid of liquids. Patients should not chew, divide, or crush tablets. The medication is contained within a nonabsorbable shell designed to release the drug at a controlled rate. The tablet shell is eliminated from the body; patients should not be concerned if they occasionally notice in their stool something that looks like a tablet.


Ditropan XL® should be taken at approximately the same time each day.



Drug Interactions


The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.


Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index.


Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when Ditropan XL® was administered with ketoconazole, a potent CYP3A4 inhibitor. Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). The clinical relevance of such potential interactions is not known. Caution should be used when such drugs are co-administered.



Carcinogenesis, Mutagenesis, Impairment of Fertility


A 24-month study in rats at dosages of oxybutynin chloride of 20, 80, and 160 mg/kg/day showed no evidence of carcinogenicity. These doses are approximately 6, 25, and 50 times the maximum human exposure, based on surface area.


Oxybutynin chloride showed no increase of mutagenic activity when tested in Schizosaccharomyces pompholiciformis, Saccharomyces cerevisiae, and Salmonella typhimurium test systems.


Reproduction studies with oxybutynin chloride in the mouse, rat, hamster, and rabbit showed no definite evidence of impaired fertility.



Pregnancy


Teratogenic Effects

Pregnancy Category B


Reproduction studies with oxybutynin chloride in the mouse, rat, hamster, and rabbit showed no definite evidence of impaired fertility or harm to the animal fetus. The safety of Ditropan XL® administration to women who are or who may become pregnant has not been established. Therefore, Ditropan XL® should not be given to pregnant women unless, in the judgment of the physician, the probable clinical benefits outweigh the possible hazards.



Nursing Mothers


It is not known whether oxybutynin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Ditropan XL® is administered to a nursing woman.



Pediatric Use


The safety and efficacy of Ditropan XL® were studied in 60 children in a 24-week, open-label trial. Patients were aged 6–15 years, all had symptoms of detrusor overactivity in association with a neurological condition (e.g., spina bifida), all used clean intermittent catheterization, and all were current users of oxybutynin chloride. Study results demonstrated that administration of Ditropan XL® 5 to 20 mg/day was associated with an increase from baseline in mean urine volume per catheterization from 108 mL to 136 mL, an increase from baseline in mean urine volume after morning awakening from 148 mL to 189 mL, and an increase from baseline in the mean percentage of catheterizations without a leaking episode from 34% to 51%.


Urodynamic results were consistent with clinical results. Administration of Ditropan XL® resulted in an increase from baseline in mean maximum cystometric capacity from 185 mL to 254 mL, a decrease from baseline in mean detrusor pressure at maximum cystometric capacity from 44 cm H2O to 33 cm H2O, and a reduction in the percentage of patients demonstrating uninhibited detrusor contractions (of at least 15 cm H2O) from 60% to 28%.


Ditropan XL® is not recommended in pediatric patients who cannot swallow the tablet whole without chewing, dividing, or crushing, or in children under the age of 6 (See DOSAGE AND ADMINISTRATION).



Geriatric Use


The rate and severity of anticholinergic effects reported by patients less than 65 years old and those 65 years and older were similar (see CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Populations: Geriatric).



Adverse Reactions



Adverse Events with Ditropan XL®


The safety and efficacy of Ditropan XL® (oxybutynin chloride) were evaluated in a total of 580 participants who received Ditropan XL® in 4 clinical trials (429 patients) and four pharmacokinetic studies (151 healthy volunteers). The 429 patients were treated with 5–30 mg/day for up to 4.5 months. Three of the 4 clinical trials allowed dose adjustments based on efficacy and adverse events and one was a fixed-dose escalation design. Safety information is provided for 429 patients from these three controlled clinical studies and one open-label study in the first column of Table 3 below.


Adverse events from two additional fixed-dose, active-controlled, 12-week treatment duration, postmarketing studies, in which 576 patients were treated with Ditropan XL® 10 mg/day, are also listed in Table 3 (second column). The adverse events are reported regardless of causality.



































































Table 3 Incidence (%) of Adverse Events Reported by ≥ 5% of Patients Using Ditropan XL® (5–30 mg/day) and % of Corresponding Adverse Events in Two Fixed-Dose (10 mg/day) Studies
Ditropan XL®Ditropan XL®
Body SystemAdverse Event5–30 mg/day

(n=429)
10 mg/day

(n=576)
Generalheadache106
asthenia73
pain74
Digestivedry mouth6129
constipation137
diarrhea97
nausea92
dyspepsia75
Nervoussomnolence122
dizziness64
Respiratoryrhinitis62
Special sensesblurred vision81
dry eyes63
Urogenitalurinary tract infection55

The most common adverse events reported by the 429 patients receiving 5–30 mg/day Ditropan XL® were the expected side effects of anticholinergic agents. The incidence of dry mouth was dose-related.


The discontinuation rate for all adverse events was 6.8% in the 429 patients from the 4 studies of efficacy and safety who received 5–30 mg/day. The most frequent adverse event causing early discontinuation of study medication was nausea (1.9%), while discontinuation due to dry mouth was 1.2%.


In addition, the following adverse events were reported by ≥ 1 to < 5% of all patients who received Ditropan XL® in the 6 adjustable and fixed-dose efficacy and safety studies. Infections and infestations: nasopharyngitis, upper respiratory tract infection, sinusitis, bronchitis, cystitis; Psychiatric disorders: insomnia, depression, nervousness, confusional state; Nervous System Disorders: dysgeusia; Cardiac disorders: palpitations; Vascular disorders: hypertension; Respiratory, thoracic and mediastinal disorders: nasal dryness, cough, pharyngolaryngeal pain, dry throat; Gastrointestinal Disorders: gastroesophageal reflux disease, abdominal pain, loose stools, flatulence, vomiting; Skin and subcutaneous tissue disorders: dry skin, pruritis; Musculoskeletal and connective tissue disorders: back pain, arthralgia, pain in extremity; Renal and urinary disorders: urinary retention, urinary hesitation, dysuria; General disorders and administration site conditions: fatigue, edema peripheral, asthenia, chest pain; Investigations: blood pressure increased.



Postmarketing Surveillance


Because postmarketing reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following additional adverse drug reactions have been reported from worldwide postmarketing experience with Ditropan XL®: Psychiatric Disorders: psychotic disorder, agitation, hallucinations, memory impairment; Nervous System Disorders: convulsions; Eye Disorders: glaucoma; Cardiac Disorders: arrhythmia, tachycardia, QT interval prolongation; Vascular Disorders: flushing; Skin and Subcutaneous Tissue Disorders: rash; Renal and Urinary Disorders: impotence; General Disorders and Administration Site Conditions: hypersensitivity reactions, including angioedema with airway obstruction, urticaria, and face edema; rare anaphylactic reactions requiring hospitalization for emergency treatment; Injury, poisoning and procedural complications: fall.


Additional adverse events reported with some other oxybutynin chloride formulations include: cycloplegia, mydriasis, and suppression of lactation.



Overdosage


The continuous release of oxybutynin from Ditropan XL® (oxybutynin chloride) should be considered in the treatment of overdosage. Patients should be monitored for at least 24 hours. Treatment should be symptomatic and supportive. Activated charcoal as well as a cathartic may be administered.


Overdosage with oxybutynin chloride has been associated with anticholinergic effects including central nervous system excitation, flushing, fever, dehydration, cardiac arrhythmia, vomiting, and urinary retention.


Ingestion of 100 mg oxybutynin chloride in association with alcohol has been reported in a 13-year-old boy who experienced memory loss, and a 34-year-old woman who developed stupor, followed by disorientation and agitation on awakening, dilated pupils, dry skin, cardiac arrhythmia, and retention of urine. Both patients fully recovered with symptomatic treatment.



Ditropan XL Dosage and Administration


Ditropan XL® (oxybutynin chloride) must be swallowed whole with the aid of liquids, and must not be chewed, divided, or crushed.


Ditropan XL® may be administered with or without food.



Adults


The recommended starting dose of Ditropan XL® is 5 or 10 mg once daily at approximately the same time each day. Dosage may be adjusted in 5-mg increments to achieve a balance of efficacy and tolerability (up to a maximum of 30 mg/day). In general, dosage adjustment may proceed at approximately weekly intervals.



Pediatric Patients Aged 6 Years of Age and Older


The recommended starting dose of Ditropan XL® is 5 mg once daily at approximately the same time each day. Dosage may be adjusted in 5-mg increments to achieve a balance of efficacy and tolerability (up to a maximum of 20 mg/day).



How is Ditropan XL Supplied


Ditropan XL® (oxybutynin chloride) Extended Release Tablets are available in three dosage strengths, 5 mg (pale yellow), 10 mg (pink), and 15 mg (gray) and are imprinted with "5 XL", "10 XL", or "15 XL". Ditropan XL® Extended Release Tablets are supplied in bottles of 100 tablets.











5 mg100 count bottleNDC 50458-805-01
10 mg100 count bottleNDC 50458-810-01
15 mg100 count bottleNDC 50458-815-01

Storage


Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature]. Protect from moisture and humidity.



For more information call 1-888-395-1232 or visit www.DITROPANXL.com


Manufactured by:

ALZA Corporation, Vacaville, CA 95688


An ALZA OROS® Technology Product


Ditropan XL® and OROS® are registered trademarks of ALZA Corporation.


Manufactured for:

Ortho Women's Health & Urology, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Raritan, NJ 08869


Placeholder for Ortho Women's Health & Urology, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Logo


© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1998


10192603


Revised December 2011



PRINCIPAL DISPLAY PANEL - 5 mg 100 tablet bottle


NDC 50458-805-01

100 tablets


Ditropan XL®

(oxybutynin chloride)

Extended-release tablets


5 mg


Rx only


Ditropan XL®and OROS®are registered

trademarks of ALZA Corporation.




PRINCIPAL DISPLAY PANEL - 10 mg 100 tablet bottle


NDC 50458-810-01

100 tablets


Ditropan XL®

(oxybutynin chloride)

Extended-release tablets


10 mg


Rx only


Ditropan XL®and OROS®are registered

trademarks of ALZA Corporation.




PRINCIPAL DISPLAY PANEL - 15 mg 100 tablet bottle


NDC 50458-815-01

100 tablets


Ditropan XL®

(oxybutynin chloride)

Extended-release tablets


15 mg


Rx only


Ditropan XL®and OROS®are registered

trademarks of ALZA Corporation.










DITROPAN  XL
oxybutynin chloride  tablet, extended release










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)50458-805
Route of AdministrationORALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
oxybutynin chloride (oxybutynin)oxybutynin chloride5 mg






















Inactive Ingredients
Ingredient NameStrength
cellulose acetate 
hypromelloses 
lactose 
magnesium stearate 
polyethylene glycols 
titanium dioxide 
polysorbate 80 
sodium chloride 
butylated hydroxytoluene 


















Product Characteristics
ColorYELLOW (pale yellow)Scoreno score
ShapeROUNDSize8mm
FlavorImprint Code5;XL
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
150458-805-01100 TABLET In 1 BOTTLENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA02089706/26/1999







DITROPAN  XL
oxybutynin chloride  tablet, extended release










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)50458-810
Route of AdministrationORALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
oxybutynin chloride (oxybutynin)oxybutynin chloride10 mg






















Inactive Ingredients
Ingredient NameStrength
cellulose acetate 
hypromelloses 
lactose 
magnesium stearate 
polyethylene glycols 
titanium dioxide 
polysorbate 80 
sodium chloride 
butylated hydroxytoluene 


















Product Characteristics
ColorPINKScoreno score
ShapeROUNDSize8mm
FlavorImprint Code10;XL
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
150458-810-01100 TABLET In 1 BOTTLENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA02089706/26/1999







DITROPAN  XL
oxybutynin chloride  tablet, extended release










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)50458-815
Route of AdministrationORALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
oxybutynin chloride (oxybutynin)oxybutynin chloride15 mg






















Inactive Ingredients
Ingredient NameStrength
cellulose acetate 
hypromelloses 
lactose 
magnesium stearate 
polyethylene glycols 
titanium dioxide 
polysorbate 80 
sodium chloride 
butylated hydroxytoluene 


















Product Characteristics
ColorGRAYScoreno score
ShapeROUNDSize8mm
FlavorImprint Code15;XL
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
150458-815-01100 TABLET In 1 BOTTLENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA02089706/26/1999


Labeler - Janssen Pharmaceuticals, Inc. (063137772)







Establishment
NameAddressID/FEIOperations
PCAS France (API)

Omeprazole Tablets




Dosage Form: tablet, delayed release
Omeprazole Delayed Release Tablets, 20 mg

Omeprazole Delayed Release Tablets, 20 mg Drug Facts




Active ingredient (in each tablet)

Omeprazole delayed-release tablet, 20 mg

Purpose
Acid reducer




Use
  • treats frequent heartburn (occurs 2 or more days a week)

  • not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect




Warning

Allergy alert:  Do not use if you are allergic to omeprazole

Do not use if you have trouble or pain swallowing food, vomiting with blood, or bloody or black stools.  These may be signs of a serious condition.  See your doctor.



Ask a doctor before use if you have


  • had heartburn over 3 months.  This may be a sign of a more serious condition.

  • heartburn with lightheadedness, sweating or dizziness

  • chest pain or shoulder pain with shortness or breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness

  • frequent chest pain

  • frequent wheezing, particularly with heartburn

  • unexplained weight loss

  • nausea or vomiting

  • stomach pain


Ask a doctor or pharmacist before use if you are taking


  • clopidogrel bisulfate (anti-blood clotting medicine)

  • warfarin (blood-thinning medicine)

  • prescription antifungal or anti-yeast medicines

  • diazepam (anxiety medicine)

  • digoxin (heart medicine)

  • tacrolimus (immune system medicine)

  • atazanavir (medicine for HIV infection)


Stop use and ask a doctor if


  • your heartburn continues or worsens

  • you need to take this product for more than 14 days

  • you need to take more than 1 course of treatment every 4 months


If pregnant or breast-feeding, ask a health professional before use.



Keep out of reach of children.  In case of overdose, get medical help or contact a Poison Control Center right away.

(1-800-2221222)




Directions
  • adults 18 years of age and older

  • this product is to be used once a day (every 24 hours), every day for 14 days

  • it may take 1 to 4 days for full effect, although some people get complete relief of symptoms within 24 hours


14-Day Course of Treatment
  • swallow 1 tablet with a glass of water before eating in the morning

  • take every day for 14 days

  • do not take more than 1 tablet a day

  • do not chew or crush the tablets

  • do not crush tablets in food

  • do not use for more than 14 days unless directed by your doctor


Repeated 14-Day Courses (if needed)
  • you may repeat a 14-day course every 4 months

  • do not take for more than 14 days or more often than every 4 months unless directed by a doctor

  • children under 18 years of age:  ask a doctor



Other information
  • read the directions, warnings, and package insert before use

  • keep the carton and package insert.  They contain important information.

  • store at 20-25°C (68-77°F)

  • keep product out of high heat and humidity

  • protect product from moisture


Inactive ingredients carnauba wax, ferric oxide red, ferric oxide yellow, hypromellose, hypromellose acetate succinate, lactose monohydrate, monoethanolamine, propylene glycol, sodium lauryl sulfate, sodium starch glycolate, sodium stearate, sodium stearyl fumarate, talc, titanium dioxide, triethyl citrate




Questions or comments?

1-800-719-9260

Inner Carton Label




Treats Frequent Heartburn!
Occurring 2 or More Days a Week

Omeprazole

delayed release tablets 20 mg

acid reducer

14 TABLETS
One 14-day course of treatment





Blister Label




Omeprazole DR Tablets

20 mg

Acid reducer

Push tablet through foil.

Dexcel Ltd.

1 Dexcel St.  Or Akiva

30600, Israel


Do not chew or crush tablets


Do not crush tablets in food




Bottle Label




NOT FOR RESALE


Treats Frequent Heartburn!

Occurring 2 or More Days a Week


Omeprazole Delayed

Release Tablets 20 mg


Acid Reducer


14 Tablets

One 14-day course of treatment


DO NOT USE IF PRINTED SEAL UNDER CAP IS BROKEN OR MISSING


Manufactured by:

Dexcel® Ltd.

1 Dexcel St., Or Akiva

30600, Israel


Made in Israel








Patient Package Insert




Omeprazole Delayed Release Tablets 20 mg


Acid Reducer


Please read all of this package insert before taking Omeprazole Delayed Release Tablets 20 mg.  Save this to read, as you need.


How Omeperazole Delayed Release Tablets 20 mg Work For Your Frequent Heartburn


Omeprazole Delayed Release Tablets 20 mg work differently from other heartburn products, such as antacids and other acid reducers.  Omeprazole Delayed Release Tablets 20 mg stop acid production at the source - the acid pump that produces stomach acid.  Omeprazole Delayed Release Tablets 20 mg are to be used once a day (every 24 hours), every day for 14 days.


What to Expect When Using Omeprazole Delayed Release Tablets 20 mg


Omeprazole Delayed Release Tablets 20 mg are a different type of medicine from antacids and other acid reducers.  Omeprazole Delayed Release Tablets 20 mg may take 1 to 4 days for full effect, although some people get complete relief of symptoms within 24 hours.  Make sure you take the entire 14 days of dosing to treat your frequent heartburn.


Safety Record


For years, doctors have prescribed omeprazole to treat acid-related conditions in millions of people safely.


Who Should Take Omeprazole Delayed Release Tablets 20 mg


This product is for adults (18 years and older) with frequent heartburn - when you have heartburn 2 or more days a week.
  • Omeprazole Delayed Release Tablets 20 mg are not intended for those who have heartburn infrequently, one episode of heartburn a week or less, or for those who want immediate relief or heartburn.


How to Take Omeprazole Delayed Release Tablets 20 mg


14-Day Course of Treatment
  • Swallow 1 tablet with a glass of water before eating in the morning.

  • Take every day for 14 days.

  • Do not take more than 1 tablet a day

  • Do not chew or crush the tablets.

  • Do not crush tablets in food.

  • Do not use for more than 14 days unless directed by your doctor.


It is important not to chew or crush these tablets, or crush the tablets in food.  This decreases how well Omeprazole Delayed Release Tablets 20 mg work.


When to Take Omeprazole Delayed Release Tablets 20 mg Again


You may repeat a 14-day course of therapy every 4 months.


When to Talk to Your Doctor


Do not take for more than 14 days or more often than every 4 months unless directed by a doctor.


Warnings and When to Ask Your Doctor


Allergy alert:  Do not use if you are allergic to omeprazole


Do not use if you have trouble or pain swallowing food, vomiting with blood, or bloody or black stools.  These may be signs of a serious condition.  See your doctor.


Ask a doctor before use if you have
  • had heartburn over 3 months.  This may be a sign of a more serious condition

  • heartburn with lightheadedness, sweating or dizziness

  • chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness

  • frequent chest pain

  • frequent wheezing, particularly with heartburn

  • unexplained weight loss

  • nausea or vomiting

  • stomach pain


Ask a doctor or pharmacist before use if you are taking
  • clopidogrel bisulfate (anti-blood clotting medicine)

  • warfarin (blood-thinning medicine)

  • prescription antifungal or anti-yeast medicines

  • diazepam (anxiety medicine)

  • digoxin (heart medicine)

  • tacrolimus (immune system medicine)

  • atazanavir (medicine for HIV infection)


Stop use and ask a doctor if
  • your heartburn continues or worsens

  • you need to take this product for more than 14 days

  • you need to take more than 1 course of treatment every 4 months


If pregnant or breast-feeding,

ask a health professional before use.


Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away.  (1-800-222-1222)


Tips for Managing Heartburn
  • Do not lie flat or bend over soon after eating.

  • Do not eat late at night or just before bedtime.

  • Certain foods or drinks are more likely to cause heartburn, such as rich, spicy, fatty and fried foods, chocolate, caffeine, alcohol and even some fruits and vegetables.

  • Eat slowly and do not eat big meals.

  • If you are overweight, lose weight.

  • If you smoke, quit smoking.

  • Raise the head of your bed.

  • Wear loose-fitting clothing around your stomach.


How are Omeprazole Delayed Release Tablets 20 mg Sold


Omeprazole Delayed Release Tablets 20 mg are available in 14 tablet, 28 tablet and 42 tablet sizes.  These sizes contain one, two and three 14-day courses of treatment, respectively.  Do not use for more than 14 days in a row unless directed by your doctor.  For the 28 count (two 14-day courses) and the 42 count (three 14-day courses), you may repeat a 14-day course every 4 months.


For Questions or Comments About Omeprazole Delayed Release Tablets 20 mg


Call 1-800-719-9260


Made in Israel


Manufactured by:

DEXCEL® LTD.

Southern Industrial Zone

Or Akiva 30600, Israel



Bulk 7-Count Blister Pack Carton Label




70 Tablets


OMEPRAZOLE DR TABLETS 20 MG OTC

Acid reducer


FOR REPACKAGING ONLY


Manufactured by:  DEXCEL® LTD.

Southern Industrial Zone, Or Akiva 30600, Israel

  • Store at 15° - 25°C (59° - 77°F)

  • Keep product out of high heat and humidity

  • Protect product from moisture









OMEPRAZOLE   DELAYED RELEASE
omeprazole  tablet, delayed release










Product Information
Product TypeHUMAN OTC DRUGNDC Product Code (Source)64861-303
Route of AdministrationORALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Omeprazole (Omeprazole)Omeprazole20 mg


































Inactive Ingredients
Ingredient NameStrength
Carnauba Wax 
Ferric Oxide Red 
Ferric Oxide Yellow 
Hypromellose 
Hypromellose Acetate Succinate 12070923 (3 MM2/S) 
Lactose Monohydrate 
Ethanolamine 
Propylene Glycol 
Sodium Lauryl Sulfate 
Sodium Starch Glycolate Type A Potato 
Sodium Stearate 
Sodium Stearyl Fumarate 
Talc 
Titanium Dioxide 
Triethyl Citrate 


















Product Characteristics
Colorbrown (brownish)Scoreno score
ShapeOVAL (capsule-shaped)Size13mm
FlavorImprint Code20
Contains      


























Packaging
#NDCPackage DescriptionMultilevel Packaging
164861-303-0114 TABLET In 1 BOTTLE, PLASTICNone
264861-303-0210 BLISTER PACK In 1 CARTONcontains a BLISTER PACK
27 TABLET In 1 BLISTER PACKThis package is contained within the CARTON (64861-303-02)
364861-303-032 BLISTER PACK In 1 CARTONcontains a BLISTER PACK
37 TABLET In 1 BLISTER PACKThis package is contained within the CARTON (64861-303-03)










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA02203203/01/2008


Labeler - Dexcel Ltd. (600534200)









Establishment
NameAddressID/FEIOperations
Dexcel Ltd.600534200analysis, label, manufacture, pack
Revised: 04/2010Dexcel Ltd.




More Omeprazole Tablets resources


  • Omeprazole Tablets Side Effects (in more detail)
  • Omeprazole Tablets Dosage
  • Omeprazole Tablets Use in Pregnancy & Breastfeeding
  • Drug Images
  • Omeprazole Tablets Drug Interactions
  • Omeprazole Tablets Support Group
  • 46 Reviews for Omeprazoles - Add your own review/rating


Compare Omeprazole Tablets with other medications


  • Barrett's Esophagus
  • Duodenal Ulcer
  • Erosive Esophagitis
  • GERD
  • Helicobacter Pylori Infection
  • Indigestion
  • Multiple Endocrine Adenomas
  • Stomach Ulcer
  • Systemic Mastocytosis
  • Zollinger-Ellison Syndrome